- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02610361
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Chris O'Brien Lifehouse
-
Port Macquarie, New South Wales, Australia, 2444
- North Coast Cancer Institute
-
Randwick, New South Wales, Australia, 2031
- Prince of Wales Hospital
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
-
Queensland
-
Southport, Queensland, Australia, 4215
- Tasman Oncology Research Ltd
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
Woodville South, South Australia, Australia, 5011
- The Queen Elizabeth Hospital
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Box Hill Hospital
-
Clayton, Victoria, Australia, 3168
- Monash Medical Centre
-
Heidelberg, Victoria, Australia
- Austin Health
-
Malvern, Victoria, Australia, 3144
- Cabrini Hospital
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
Melbourne, Victoria, Australia
- Peter Maccallum Cancer Centre
-
Parkville, Victoria, Australia
- Royal Melbourne Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Linear Clinical Research Limited
-
-
-
-
-
Christchurch, New Zealand, 8011
- Christchurch Hospital
-
Dunedin, New Zealand, 9106
- Dunedin Public Hospital
-
Hamilton, New Zealand
- Waikato Hospital
-
Wellington, New Zealand
- Wellington Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provided written informed consent prior to enrollment.
- Male or female and at least 18 years of age.
- A life expectancy of at least 12 weeks.
- Histologically or cytologically confirmed advanced or metastatic solid tumor for which no effective standard therapy is available.
- One of B-RAF, N-RAS, or K-RAS mutation positive solid tumor.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
- Able to swallow and retain oral medication.
Adequate bone marrow, liver, and renal function:
- Hemoglobin > 9 g/dL
- Absolute neutrophil count ≥ 1000/mm^3
- Platelets ≥ 100,000/mm^3
- Total bilirubin ≤1.5 times the upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN for subjects with known liver metastasis)
- Creatinine clearance ≥ 45 mL/min (calculated by the Cockcroft Gault formula).
Female subjects are eligible to enter and participate in the study if they are of:
a) Non childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who
i) Has had a hysterectomy,
ii) Has had a bilateral oophorectomy (ovariectomy),
iii) Has had a bilateral tubal ligation, or
iv) Is post menopausal (total cessation of menses for ≥ 1 year).
b) Childbearing potential, has a negative serum pregnancy test at screening (within 7 days of the first investigational product administration), and uses adequate contraception before study entry and throughout the study until 28 days after the last investigational product administration. Adequate contraception, when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows:
i) Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
ii) Any intrauterine device with a documented failure rate of less than 1% per year.
iii) Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.
- Subjects with treated brain metastasis are eligible to enter and participate in the study if they are neurologically stable.
Exclusion Criteria:
- Female subjects who are pregnant or lactating.
- Subjects receiving cancer therapy (chemotherapy or other systemic anti cancer therapies, immunotherapy, radiation therapy, or surgery) at the time of enrollment.
- Any major surgery within 28 days prior to enrollment.
- Any radiotherapy within 14 days prior to enrollment, providing the subject has recovered from all toxicities to NCI-CTCAE ≤ Grade 1.
- Use of any investigational anti cancer drug within 28 days before the first investigational product administration.
- Unresolved toxicity > Grade 1 (according to NCI-CTCAE, Version 4.03) from previous anti cancer therapy, unless agreed by the sponsor.
- History or presence of gastrointestinal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug or to any component of BGB-283. (To date there are no known Food and Drug Administration [FDA] approved drugs chemically related to BGB-283).
- Untreated leptomeningeal or brain metastasis. Subjects with previously treated brain metastasis that are asymptomatic, off steroids for longer than 28 days are permitted.
- Any unstable, pre-existing major medical condition that in the opinion of the Investigator contra indicates the use of an investigational product, including active infection, known human immunodeficiency virus (HIV) positive subjects, or known Hepatitis B or C.
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- As a result of the medical interview, physical examination or screening investigations, the investigator considers the subject unfit for study.
- Is on medication listed in the protocol or requires any of these medications during treatment with BGB-283.
- Candidates for curative therapy.
- Unable or unwilling to comply with the required treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BGB-283
|
In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme. In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events in phase 1a
Time Frame: From first dose to within 28 days of last dose of BGB-283, within 1 years in average
|
From first dose to within 28 days of last dose of BGB-283, within 1 years in average
|
Objective response rate based on RECIST Version 1.1 in subjects with selected tumor types in phase 1b
Time Frame: From the first administration of the investigational product to the end of the study treatment, within 1 year in average
|
From the first administration of the investigational product to the end of the study treatment, within 1 year in average
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast) in phase 1a
Time Frame: During first 2 weeks
|
During first 2 weeks
|
Area under the plasma concentration-time curve from time 0 to infinity time in (AUC∞) in phase 1a
Time Frame: During first 2 weeks
|
During first 2 weeks
|
Maximum plasma concentration (Cmax) in phase 1a
Time Frame: During first 2 weeks
|
During first 2 weeks
|
Time to reach maximum plasma concentration (tmax) in phase 1a
Time Frame: During first 2 weeks
|
During first 2 weeks
|
Terminal elimination half-life (t1/2) in phase 1a
Time Frame: During first 2 weeks
|
During first 2 weeks
|
Tumor response in phase 1a
Time Frame: Every 6 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, within 1 year in average
|
Every 6 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, within 1 year in average
|
Number of participants with adverse events in phase 1b
Time Frame: From first dose to within 28 days of last dose of BGB-283, within 1 year in average
|
From first dose to within 28 days of last dose of BGB-283, within 1 year in average
|
Progression-free survival (PFS)
Time Frame: The interval from study treatment initiation until the determination of disease progression or death, within 1 year in average
|
The interval from study treatment initiation until the determination of disease progression or death, within 1 year in average
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jayesh Desai, MD, Peter MacCallum Cancer Centre, Australia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BGB-283-AU-001
- ACTRN12614001176651 (Registry Identifier: The Australian New Zealand Clinical Trials Registry)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
Clinical Trials on BGB-283
-
BeiGeneCompleted
-
BeiGeneSpringWorks Therapeutics, Inc.RecruitingSolid Tumor, AdultAustralia, United States
-
Boehringer IngelheimTerminatedCystic FibrosisUnited States
-
BeiGeneCompleted
-
BeiGeneTerminatedAdvanced Solid TumorsAustralia, Spain, New Zealand
-
BeiGeneRecruitingRefractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditionsChina, Australia
-
BeiGeneCompletedFor Participants With Advanced Solid Tumors Failed With Previous Lines of TreatmentAustralia
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); BerGenBio ASATerminatedBrain and Central Nervous System TumorsUnited States
-
BeiGeneMyriad Genetic Laboratories, Inc.CompletedSolid TumorsUnited States, Spain, United Kingdom, France, Australia, New Zealand
-
Fudan UniversityRecruitingLimited Stage Small Cell Lung CancerChina